Thallion Pharma’s Novel Anti-Cancer (ECO-4601), Passed Phase I/II Clinical Trial
Thallion Pharmaceuticals’ novel anti-cancer drug which offers two modes of action – ECO-4601 – showed positive results from its Phase I/II clinical trial.
According to Pierre Falardeau, Ph.D., chief operating officer at Thallion Pharmaceuticals in Montreal, Canada:
”In 26 patients with advanced solid tumors, treatment with ECO-4601 is safe and well tolerated, including at doses yielding plasma concentrations above the expected therapeutic threshold.
ECO-4601 has a unique mechanism of action comprising two distinct activities. It inhibits the RAS/MAPK intracellular signaling pathway, which is mutated in many cancer types, and which is the target of several approved cancer drugs such as Erbitux, Avastin, Tarceva, Nexavar, and Sutent.
However, unlike these drugs, our preclinical experiments suggest that ECO-4601 acts at a unique point within the pathway, specifically at the level of RAS itself.”
Produced and tested by Thallion Pharmaceuticals in association with the Segal Cancer Centre of McGill University, ECO-4601 binds to the peripheral benzodiazepine receptor (PBR), which is over-expressed in multiple cancers.
Well, the drug has to pass Phase III Clinical trials in humans before it can be approved by a regulatory agency such as the FDA.
Find more details from Science Daily.
Tags: anti-cancer-agents, ECO-4601Related Stories
POSTED IN: on anti-cancer ingredients
0 opinions for Thallion Pharma’s Novel Anti-Cancer (ECO-4601), Passed Phase I/II Clinical Trial
No one has left a comment yet. You know what this means, right? You could be first!
Have an opinion? Leave a comment: